CanSino Biologics, Inc. Class H (HK:6185)
:6185
6185 Stock Chart & Stats
HK$44.94
-HK$0.10(-0.36%)
At close: 4:00 PM EST
HK$44.94
-HK$0.10(-0.36%)
Day’s Range― - ―
52-Week RangeHK$25.25 - HK$56.55
Previous CloseN/A
Volume470.05K
Average Volume (3M)609.75K
Market Cap
HK$13.10B
Enterprise ValueHK$12.23B
Total Cash (Recent Filing)HK$2.47B
Total Debt (Recent Filing)HK$1.43B
Price to Earnings (P/E)292.7
Beta1.44
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.49
Price to Sales (P/S)8.66
P/FCF Ratio-11.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.45B
Bulls Say, Bears Say
Bulls Say
Durable Revenue Streams From Vaccine SalesDirect sales to governments, healthcare organizations and private clients, plus R&D collaborations and grants, create multiple, structurally recurring revenue channels. That diversity supports steadier demand and funding for vaccine development across funding cycles and geographies.
Focused Vaccine R&D And PipelineA concentrated business model on vaccine R&D and manufacturing (including lead Ad5-nCoV and candidates for TB and influenza) aligns with persistent global public health needs. This specialization builds technical know‑how and manufacturing scale that underpin long-term competitive positioning.
Moderate Leverage And Stable Asset BaseRelatively low debt (D/E ~0.29) and a stable equity ratio suggest financial flexibility to support ongoing R&D and production investments. Lower leverage reduces near-term solvency risk and preserves capacity to raise or allocate capital for strategic programs over the medium term.
Bears Say
Loss-making Operating MarginsSustained negative net income and EBIT margins undermine internal funding for trials, commercialization and scaling. Without a clear path to recurring profitability, the business remains reliant on external financing, which raises dilution and execution risk over the medium term.
Weak Cash Conversion And Negative Free Cash FlowNegative FCF growth and poor conversion of accounting income into operating cash constrain the company’s ability to self-finance R&D and production. Persistent cash burn increases dependence on external capital and heightens liquidity risk during prolonged development timelines.
Profitability Volatility And Negative ROEA negative ROE and historical profit volatility (peaks then downturns) signal inconsistent operational performance and capital allocation effectiveness. This makes forecasting returns and funding needs harder, increasing execution risk for long‑term commercial expansion.
CanSino Biologics, Inc. Class H News
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$25.25 and its highest was HK$56.55 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$13.10B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Apr 29, 2026 which is in 22 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.061 earnings per share for the quarter, missing the consensus estimate of HK$0.352 by -HK$0.29.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Overvalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of HK$0.061 in its last earnings report, missing expectations of HK$0.352. Following the earnings report the stock price went up 0.682%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.91%
12-Months-Change
Fundamentals
Return on Equity
0.56%
Trailing 12-Months
Asset Growth
-5.67%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Options Prices
Currently, No data available
---